Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

about

Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.Molecular diagnosis and treatment of drug-resistant hepatitis B virus.

P2860

Q35846564-C71686CA-0038-4E0E-B18A-2AF99A7B8655 Q38219020-623BFA84-024B-4CF8-840D-356631DD193E

P2860

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

Item

http://www.wikidata.org/entity/Q46044243

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@en

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@nl

type

Item

label

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@en

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@nl

prefLabel

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@en

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

@nl

P1476

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

@en

P2093

Man-Fung Yuen

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in Molecular Diagnosis of HBV Infection and Drug Resistance

Telbivudine versus lamivudine in patients with chronic hepatitis B

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

Acyclic nucleoside phosphonates: a key class of antiviral drugs.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Continuous antiretroviral therapy decreases bone mineral density.

P2888

s12072-011-9282-y

P304

327-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-011-9282-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Fung

Ching-Lung Lai

Seto WK

P577

2011-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21688182

http://www.w3.org/2001/XMLSchema#string

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

about

P2860

P2860

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698